Exact Mass: 467.07472980000006
Exact Mass Matches: 467.07472980000006
Found 76 metabolites which its exact mass value is equals to given mass value 467.07472980000006
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
AG 2034
(2S)-2-[[5-[2-[(6S)-2-Amino-4-oxo-1,6,7,8-tetrahydropyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
Bepafant
C23H22ClN5O2S (467.11826620000005)
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
FK-614
C21H23Cl2N3O3S (467.08371080000006)
4-(3-Chloro-2-cyanophenoxy)-N-(4-piperidinophenyl)benzenesulfonamide
C24H22ClN3O3S (467.10703320000005)
Cys Cys Asp Gln
Cys Cys Glu Asn
Cys Cys Asn Glu
Cys Cys Gln Asp
Cys Asp Cys Gln
Cys Asp Gln Cys
Cys Glu Cys Asn
Cys Glu Asn Cys
Cys Asn Cys Glu
Cys Asn Glu Cys
Cys Gln Cys Asp
Cys Gln Asp Cys
Asp Cys Cys Gln
Asp Cys Gln Cys
Asp Gln Cys Cys
Glu Cys Cys Asn
Glu Cys Asn Cys
Glu Asn Cys Cys
Asn Cys Cys Glu
Asn Cys Glu Cys
Asn Glu Cys Cys
Gln Cys Cys Asp
Gln Cys Asp Cys
Gln Asp Cys Cys
N-[4-(4-amino-7-cyclopentylpyrrolo[2,3-d]pyrimidin-5-yl)-2-chlorophenyl]benzenesulfonamide
C23H22ClN5O2S (467.11826620000005)
3-[[4-(2,4,6-trinitroanilino)benzoyl]amino]benzoic acid
C20H13N5O9 (467.07132480000007)
2 6-DICHLORO-4-(2 4 6-TRIPHENYL-1-PYRI-&
C29H19Cl2NO (467.08436240000003)
disodium,3-[4-[(5-nitropyridin-2-yl)diazenyl]-3-oxido-N-propylanilino]propane-1-sulfonate
(5AS, 10BR)-(-)-5A,10B-DIHYDRO-2-(PENTAFLUOROPHENYL)-4H,6H-INDENO[2,1-B][1,2,4]TRIZOLO[4,3-D][1,4]OXAZINIUM TETRAFLUOROBORATE
dimethyl 2-[[1-(4-chlorobenzoyl)-2-(trifluoromethyl)indol-3-yl]methyl]propanedioate
C22H17ClF3NO5 (467.07472980000006)
2-Pentafluorophenyl-6,10b-dihydro-4H,5aH-5-oxo-3,10c-diaza-2-azoniacyclopenta[c]fluorine tetrafluoroborate
(S)-Fmoc-phenylalanine-4-sulfonic acid
C24H21NO7S (467.10386760000006)
1-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-1H-benzo[d]imidazole-6-carboxamide
C21H23Cl2N3O3S (467.08371080000006)
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes[1][2].
2-(6-Chloro-3-{[2,2-difluoro-2-(1-oxido-2-pyridinyl)ethyl]amino}-2-oxo-1(2H)-pyrazinyl)-N-[(2-fluorophenyl)methyl]acetamide
N-[4-(4-fluorophenyl)-2-thiazolyl]-2-[(4-methylphenyl)sulfonylamino]benzamide
C23H18FN3O3S2 (467.07735699999995)
N-(4-chlorophenyl)-2-[[4-(4-methoxyphenyl)-5-[(1-methyl-2-pyrrolyl)methyl]-1,2,4-triazol-3-yl]thio]acetamide
C23H22ClN5O2S (467.11826620000005)
N-(1,3-benzodioxol-5-yl)-2-[[6-methyl-4-oxo-3-(phenylmethyl)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]thio]acetamide
C23H21N3O4S2 (467.09734260000005)
2-[[5-[2-(2-Amino-4-oxo-3,6,7,8-tetrahydropyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]thiophene-2-carbonyl]amino]pentanedioic acid
8-Demethyl-8-formylriboflavin 5-phosphate
C17H16N4O10P-3 (467.06040260000003)
2-(3-Hydroxymercurio-2-methoxypropylcarbamoyl)phenoxyacetic acid
5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-3,3-dichloro-1H-indol-2-one
C20H19Cl2N3O4S (467.0473274000001)
Benzyl 2-[3-[3-(furan-2-ylmethylamino)-3-oxopropyl]-2,4-dioxothieno[3,2-d]pyrimidin-1-yl]acetate
C23H21N3O6S (467.11510060000006)
N-Cyclopentyl-4-[4-(furan-2-carbonyl)-piperazine-1-sulfonyl]-benzenesulfonamide
2-[[5-[[2-(3-Chloroanilino)-4-thiazolyl]methyl]-4-(3-methoxypropyl)-1,2,4-triazol-3-yl]thio]acetic acid methyl ester
C19H22ClN5O3S2 (467.08525320000007)
3-Bromo-5-[[4-[hydroxy(diphenyl)methyl]-1-piperidinyl]-oxomethyl]-2-pyranone
C24H22BrNO4 (467.07321120000006)
3-[4-(4-Morpholinylsulfonyl)phenyl]propanoic acid [2-[(5-chloro-2-pyridinyl)amino]-2-oxoethyl] ester
C20H22ClN3O6S (467.0917782000001)
N-(4-fluorophenyl)-2-[[5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-[(4-methoxyphenyl)methyl]acetamide
5-[(3-Carboxylato-5-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)(2-sulfonatophenyl)methyl]-2-hydroxy-3-methylbenzoate
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 3-hydroxybenzoate
L-Glutamic acid, N-((5-(2-((6S)-2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido(5,4-b)(1,4)thiazin-6-yl)ethyl)-2-thienyl)carbonyl)-
Lp-PLA2-IN-3
C20H13ClF3N3O3S (467.0318214000001)
Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2)[1].
(2r)-3-({2-ethyl-4,5,9-trihydroxy-10-oxobenzo[b]fluoren-11-yl}sulfanyl)-2-[(1-hydroxyethylidene)amino]propanoic acid
C24H21NO7S (467.10386760000006)
4,4-dichloro-n-{5-chloro-4-methyl-1-oxo-1-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]pentan-2-yl}-n,3-dimethylbutanamide
C19H28Cl3N3O2S (467.09677180000006)